Allucent Executive and Leadership Team

Paula Stafford, the Chief Executive Officer at Allucent, directs the overarching corporate strategy and global vision for drug development services. Overseeing operations across 60 countries, the Chief Executive Officer ensures alignment between internal resources and the complex requirements of pharmaceutical clients. This leadership role involves driving long-term growth while maintaining the high standards of clinical research excellence expected within the industry. By fostering an individualized partnership model, Paula Stafford enables the organization to navigate regulatory hurdles and deliver novel treatments to patients worldwide. The Chief Executive Officer collaborates closely with the board to refine the company mission, ensuring that all departments remain focused on the core objective of advancing therapeutic innovation. Through consistent oversight of international market expansion, Stafford secures the competitive position of the firm within the global research and development landscape.

Howard Brand, the Chief Financial Officer at Allucent, directs the financial planning, fiscal reporting, and capital allocation strategies for the global organization. Overseeing the economic health of the company, the Chief Financial Officer ensures that resources are effectively distributed to support drug development projects across diverse therapeutic areas. This leadership role involves managing the financial complexities of operating in over 60 countries while maintaining strict compliance with international accounting standards. By analyzing revenue streams and operational costs, Howard Brand provides the strategic insights necessary for sustainable growth. The Chief Financial Officer collaborates with the executive team to evaluate investment opportunities that enhance the service capabilities of the firm. Through rigorous financial oversight and risk management, Brand secures the long-term stability of the business, ensuring that the organization possesses the necessary capital to continue delivering innovative solutions to the pharmaceutical industry.

Leslie Devos, the President, Product Development Strategy at Allucent, directs the scientific framework and strategic planning for drug development programs. Overseeing the integration of experience-driven insights, the President, Product Development Strategy ensures that client projects align with current regulatory and therapeutic standards. This leadership role involves guiding the development of customized solutions that address the unique challenges of novel treatments. By leveraging 30 years of industry expertise, Leslie Devos architects pathways that accelerate the journey from early-stage research to patient delivery. The President, Product Development Strategy collaborates with clinical teams to refine methodologies that improve success rates in complex therapeutic areas. Through the application of deep scientific knowledge, Devos drives the innovation agenda of the firm, ensuring that the company remains a trusted partner for pharmaceutical clients seeking to navigate the intricacies of the global drug development landscape.

Anita Nelsen, the President, Clinical Trial Operations at Allucent, directs the execution and management of clinical trials across the global footprint of the company. Overseeing the daily activities of research teams, the President, Clinical Trial Operations ensures that all studies adhere to rigorous quality and safety protocols. This leadership role involves coordinating resources across 60 countries to maintain the efficiency of trial timelines and data collection processes. By implementing standardized operational procedures, Anita Nelsen facilitates the smooth delivery of clinical services for diverse therapeutic areas. The President, Clinical Trial Operations works closely with project managers to resolve logistical challenges and ensure that client objectives are met with precision. Through the oversight of large-scale clinical programs, Nelsen drives the operational excellence of the firm, directly impacting the ability of the organization to bring novel treatments to patients who require them.

Steffany Cox, the Chief Marketing Officer at Allucent, architects the global brand identity and market positioning for comprehensive drug development solutions. Managing the communication strategy, the Chief Marketing Officer drives engagement with pharmaceutical partners by highlighting the 30 years of experience inherent in the company portfolio. This role involves translating complex clinical service offerings into clear value propositions that resonate with international stakeholders. By analyzing market trends across diverse therapeutic areas, Steffany Cox ensures that the brand remains at the forefront of the research and development sector. The Chief Marketing Officer coordinates with internal teams to produce insights-driven content that supports business development goals. Through the implementation of targeted digital campaigns and industry outreach, Cox strengthens the market presence of the firm, ultimately facilitating the connection between innovative drug development services and the patients requiring life-saving treatments.

Nathan Thompson, the Chief Information Officer at Allucent, directs the digital infrastructure and data management systems essential for global clinical research operations. Overseeing the security and scalability of technological platforms, the Chief Information Officer ensures that data integrity remains a priority during the drug development lifecycle. This leadership role involves integrating advanced analytics tools to support the complex requirements of international trials. By modernizing the IT framework, Nathan Thompson enables seamless collaboration across the 60 countries where the company maintains operations. The Chief Information Officer works alongside other executive leaders to implement robust cybersecurity measures that protect sensitive client information. Through the optimization of internal systems, Thompson drives operational efficiency, allowing the firm to deliver high-quality research insights with greater speed and precision, ultimately supporting the successful delivery of novel treatments to patients in need.